Xlife Sciences (Switzerland) Insiders
| XLS Stock | 18.90 0.50 2.58% |
Xlife Sciences employs about 13 people. The company is managed by 9 executives with a total tenure of roughly 31 years, averaging almost 3.0 years of service per executive, having 1.44 employees per reported executive. Recap of Xlife Sciences' management performance can provide insight into the venture performance.
| Oliver Baumann CEO CEO Director |
| Martin Steiner CEO CEO GmbH |
Xlife |
Xlife Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0247) % which means that it has lost $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1974 %, meaning that it generated $0.1974 on every $100 dollars invested by stockholders. Xlife Sciences' management efficiency ratios could be used to measure how well Xlife Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Xlife Sciences Workforce Comparison
Xlife Sciences AG is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 20,739. Xlife Sciences adds roughly 13.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of 56.63 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (15.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $15.13. Xlife Sciences AG Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Xlife Sciences AG Price Series Summation is a cross summation of Xlife Sciences price series and its benchmark/peer.
Xlife Sciences Notable Stakeholders
A Xlife Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xlife Sciences often face trade-offs trying to please all of them. Xlife Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xlife Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Oliver Baumann | CEO Director | Profile | |
| Martin Steiner | CEO GmbH | Profile | |
| Matthias Steffen | Managing GmbH | Profile | |
| Dennis Lennartz | Head DACH | Profile | |
| Beat Klaui | Head Taxation | Profile | |
| Christian Faber | Chief Compliance | Profile | |
| Frank Ploger | Chief Officer | Profile | |
| Carl Halem | Chief Officer | Profile | |
| Christoph Antz | Chief GmbH | Profile |
About Xlife Sciences Management Performance
The success or failure of an entity such as Xlife Sciences AG often depends on how effective the management is. Xlife Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xlife management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xlife management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Xlife Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xlife Sciences AG. Check Xlife Sciences' Beneish M Score to see the likelihood of Xlife Sciences' management manipulating its earnings.
Xlife Sciences Workforce Analysis
Traditionally, organizations such as Xlife Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xlife Sciences within its industry.Xlife Sciences Manpower Efficiency
Return on Xlife Sciences Manpower
| Revenue Per Employee | 62K | |
| Revenue Per Executive | 89.6K | |
| Net Income Per Employee | 4.1M | |
| Net Income Per Executive | 5.9M |
Additional Tools for Xlife Stock Analysis
When running Xlife Sciences' price analysis, check to measure Xlife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xlife Sciences is operating at the current time. Most of Xlife Sciences' value examination focuses on studying past and present price action to predict the probability of Xlife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xlife Sciences' price. Additionally, you may evaluate how the addition of Xlife Sciences to your portfolios can decrease your overall portfolio volatility.